Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.46% | -62.57% | -15.22% | 32.21% | 81.52% |
| Total Depreciation and Amortization | 200.00% | 100.00% | -- | -- | -99.95% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.11% | 7.77% | -48.75% | -88.70% | -97.24% |
| Change in Net Operating Assets | 9,680.65% | -350.35% | -344.06% | 107.08% | -98.57% |
| Cash from Operations | -5.83% | -104.59% | -62.06% | 3.08% | 14.96% |
| Capital Expenditure | -- | -14.29% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -14.29% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -1.10% | -- |
| Repurchase of Common Stock | 99.02% | 92.98% | -- | -- | 65.54% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,889.54% | 1,857.50% | -- | -1.40% | 42.91% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.09% | -47.52% | -62.23% | -0.56% | 15.54% |